Moving Toward Rationale Phase 3 Designs for Advanced NSCLC

J Thorac Oncol. 2023 Dec;18(12):1629-1631. doi: 10.1016/j.jtho.2023.09.1439.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Carcinoma, Non-Small-Cell Lung*
  • Humans
  • Lung Neoplasms*

Substances

  • Antibodies, Monoclonal